Patents by Inventor Gerald Horn

Gerald Horn has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240091207
    Abstract: The present invention is related to methods of stabilizing an ophthalmic drug by adding a surfactant and a viscosity enhancer to the ophthalmic drug to create a composition wherein the composition has a viscosity of about 25 centipoise or less at a shear rate of 1/1000 per second at 25 degrees Celsius and a viscosity of about 70 centipoise or more at shear rate of 1 per second at 25 degrees Celsius, filling the composition into a container; and storing the container at a temperature from about 2 degrees Celsius to about 25 degrees Celsius. The present invention is further directed to a container prepared by the methods of the present invention.
    Type: Application
    Filed: September 18, 2023
    Publication date: March 21, 2024
    Inventor: Gerald HORN
  • Publication number: 20230414587
    Abstract: The present invention is related to methods of stabilizing an ophthalmic drug by adding a surfactant and a viscosity enhancer to the ophthalmic drug to create a composition wherein the composition has a viscosity of about 25 centipoise or less at a shear rate of 1/1000 per second at 25 degrees Celsius and a viscosity of about 70 centipoise or more at shear rate of 1 per second at 25 degrees Celsius, filling the composition into a container; and storing the container at a temperature from about 2 degrees Celsius to about 25 degrees Celsius. The present invention is further directed to a container prepared by the methods of the present invention.
    Type: Application
    Filed: August 28, 2023
    Publication date: December 28, 2023
    Inventor: Gerald HORN
  • Publication number: 20230414494
    Abstract: Provided herein is an ophthalmological composition and methods for the treatment of presbyopia. In some embodiments, the ophthalmological composition comprises aceclidine and brimonidine.
    Type: Application
    Filed: September 12, 2023
    Publication date: December 28, 2023
    Inventor: Gerald HORN
  • Publication number: 20230414493
    Abstract: The invention generally relates to compositions for inducing vasoconstriction. The compositions comprise highly selective alpha-2 adrenergic receptor agonists, at low concentrations, such as below 0.05% weight by volume. The compositions preferably comprise brimonidine. The compositions preferably have pH between about 5.5 and about 6.5.
    Type: Application
    Filed: May 10, 2023
    Publication date: December 28, 2023
    Inventor: Gerald HORN
  • Publication number: 20230404912
    Abstract: The invention provides compositions and methods for the treatment of presbyopia. The compositions preferably comprise aceclidine. The compositions optionally contain a surfactant and a viscosity agent.
    Type: Application
    Filed: September 1, 2023
    Publication date: December 21, 2023
    Inventor: Gerald HORN
  • Publication number: 20230398064
    Abstract: The invention provides compositions and methods for the treatment of presbyopia. The compositions comprise aceclidine hydrochloride, polysorbate 80, mannitol, anhydrous hypromellose, disodium edetate dihydrate, benzalkonium chloride, sorbic acid and anhydrous sodium citrate and optionally tropicamide.
    Type: Application
    Filed: August 28, 2023
    Publication date: December 14, 2023
    Inventors: Gerald HORN, Lee NORDAN
  • Publication number: 20230398113
    Abstract: The present invention is directed to compositions for and methods for the treatment of presbyopia comprising from about 0.3% to about 2.0% w/v aceclidine and from about 0.07% to about 0.15% w/v brimonidine.
    Type: Application
    Filed: August 28, 2023
    Publication date: December 14, 2023
    Inventor: Gerald HORN
  • Patent number: 11833245
    Abstract: The invention generally relates to compositions for inducing vasoconstriction. The compositions comprise highly selective alpha-2 adrenergic receptor agonists, at low concentrations, such as below 0.05% weight by volume. The compositions preferably comprise brimonidine. The compositions preferably have pH between about 5.5 and about 6.5.
    Type: Grant
    Filed: January 30, 2023
    Date of Patent: December 5, 2023
    Assignee: Eye Therapies LLC
    Inventor: Gerald Horn
  • Publication number: 20230338280
    Abstract: The present invention is directed to methods for improving night vision and visual performance in low light conditions comprising ophthalmological administration of compositions comprising low dose brimonidine and a vehicle for improved performance.
    Type: Application
    Filed: June 14, 2023
    Publication date: October 26, 2023
    Inventor: Gerald Horn
  • Publication number: 20230310392
    Abstract: The present invention is directed to compositions for and methods for the treatment of presbyopia, irregular astigmatism, and/or refractive error comprising from about 0.1% to about 4.0% w/w of a muscarinic agonist and from about 0.07% to about 0.15% w/w brimonidine.
    Type: Application
    Filed: April 17, 2023
    Publication date: October 5, 2023
    Inventor: Gerald Horn
  • Publication number: 20230285286
    Abstract: The invention is directed to topical drug vehicle platform compositions for ophthalmological and dermatological use. These compositions are capable of solubilizing active ingredients having a logP value of more than about 3.0 and/or having a solubility in deionized water of about 33,000 parts per million or less at 25° C.
    Type: Application
    Filed: January 23, 2023
    Publication date: September 14, 2023
    Inventors: Gerald Horn, Siddharth Narendran, Venkat Goskonda
  • Publication number: 20230248644
    Abstract: The present invention is directed to treating presbyopia, irregular astigmatism, and/or refractive error, comprising administering a composition comprising from about 0.1% to about 3.5% w/v of aceclidine to a subject in need thereof, wherein administration occurs 2 or more times within 24 hours of initial administration.
    Type: Application
    Filed: April 17, 2023
    Publication date: August 10, 2023
    Inventor: Gerald Horn
  • Patent number: 11717478
    Abstract: The present invention is directed to methods for improving night vision and visual performance in low light conditions comprising ophthalmological administration of compositions comprising low dose brimonidine and a vehicle for improved performance.
    Type: Grant
    Filed: May 12, 2021
    Date of Patent: August 8, 2023
    Assignee: EYE THERAPIES LLC
    Inventor: Gerald Horn
  • Publication number: 20230235247
    Abstract: The invention provides contact lens storage, cleaning and treatment compositions comprising nonionic surfactants. The invention further provides methods for treating enhancing contact lens wear time and comfort, reducing contact lens deposits and treating dry eye via contact lenses.
    Type: Application
    Filed: April 4, 2023
    Publication date: July 27, 2023
    Inventor: Gerald Horn
  • Publication number: 20230190739
    Abstract: The present invention is directed to compositions for and methods for the treatment of presbyopia comprising from about 0.3% to about 2.0% w/v aceclidine and from about 0.07% to about 0.15% w/v brimonidine.
    Type: Application
    Filed: December 6, 2022
    Publication date: June 22, 2023
    Inventor: Gerald Horn
  • Publication number: 20230190738
    Abstract: The present invention is directed to compositions for and methods for the treatment of presbyopia, irregular astigmatism, and/or refractive error comprising from about 0.1% to about 4.0% w/v of a muscarinic agonist and from about 0.07% to about 0.15% w/v brimonidine.
    Type: Application
    Filed: December 16, 2021
    Publication date: June 22, 2023
    Inventor: Gerald Horn
  • Publication number: 20230172841
    Abstract: The invention generally relates to compositions for inducing vasoconstriction. The compositions comprise highly selective alpha-2 adrenergic receptor agonists, at low concentrations, such as below 0.05% weight by volume. The compositions preferably comprise brimonidine. The compositions preferably have pH between about 5.5 and about 6.5.
    Type: Application
    Filed: January 30, 2023
    Publication date: June 8, 2023
    Inventor: Gerald HORN
  • Publication number: 20230151000
    Abstract: The present invention is directed to derivatives of aceclidine. The present invention is further directed to ophthalmological compositions comprising a therapeutically effective amount of a compound of the present invention and one or more pharmaceutically acceptable excipients. The present invention is further directed to a methods of treating presbyopia or glaucoma or reducing hyperemia comprising administering to a patient in need thereof a therapeutically effective amount of a compound of the present invention.
    Type: Application
    Filed: November 16, 2022
    Publication date: May 18, 2023
    Inventor: Gerald Horn
  • Patent number: 11648247
    Abstract: The present invention is directed to compositions for and methods for the treatment of presbyopia comprising from about 0.3% to about 2.0% w/v aceclidine and from about 0.07% to about 0.15% w/v brimonidine.
    Type: Grant
    Filed: December 16, 2021
    Date of Patent: May 16, 2023
    Assignee: Lenz Therapeutics, Inc.
    Inventor: Gerald Horn
  • Patent number: 11623917
    Abstract: The present invention is directed to multi-tyrosine kinase inhibitor compounds. The present invention is further directed to compositions comprising those compounds. Finally, the present invention is directed to methods of treating eye conditions including, but not limited to, diabetic background retinopathy, diabetic macular edema, diabetic proliferative retinopathy, diabetic macular edema with proliferative retinopathy, proliferative fibrovascular disease, diabetic macular edema with proliferative fibrovascular disease, retinopathy of prematurity, dry macular degeneration, dry macular degeneration with drusen and wet macular degeneration, using compounds and compositions of the invention.
    Type: Grant
    Filed: December 11, 2020
    Date of Patent: April 11, 2023
    Assignee: Ontogenesis, LLC
    Inventor: Gerald Horn